Literature DB >> 34296378

CircTMC5 promotes gastric cancer progression and metastasis by targeting miR-361-3p/RABL6.

Peng Xu1,2, XiaoLan Xu3, Xiao Wu4, LiXiang Zhang5, Lei Meng5, ZhangMing Chen5, WenXiu Han5, Jie Yao6, AMan Xu7,8.   

Abstract

BACKGROUND: Gastric cancer (GC) is common in East Asia, yet its molecular and pathogenic mechanisms remain unclear. Circular RNAs (circRNAs) are differentially expressed in GC and may be promising biomarkers. Here, we investigated the role and regulatory mechanism of circTMC5 in GC.
METHODS: CircTMC5 expression was detected in human GC and adjacent tissues using microarray assays and qRT-PCR, while the clinicopathological characteristics of patients with GC were used to assess its diagnostic and prognostic value. The circTMC5/miR-361-3p/RABL6 axis was examined in vitro and vivo, and the immune roles of RABL6 were evaluated using bioinformatics analyses and immunohistochemistry (IHC).
RESULTS: CircTMC5 was highly expressed in GC tissues, plasma, and cell lines, and was closely related to histological grade, pathological stage, and T classification in patients with GC. CircTMC5 expression was also an independent prognostic factor for GC and its combined detection with carcinoembryonic antigen may improve GC diagnosis. Low circTMC5 expression correlated with good prognosis, inhibited GC cell proliferation, and promoted apoptosis. Mechanistically, circTMC5 overexpression promoted GC cell proliferation, invasion, and metastasis but inhibited apoptosis by sponging miR-361-3p and up-regulating RABL6 in vitro and vivo, whereas miR-361-3p up-regulation had the opposite effects. RABL6 was highly expressed in GC and was involved in immune regulation and infiltration in GC.
CONCLUSIONS: CircTMC5 promotes GC and sponges miR-361-3p to up-regulate RABL6 expression, thus may have diagnostic and prognostic value in GC. RABL6 also displays therapeutic promise due to its role in the immune regulation of GC.
© 2021. The International Gastric Cancer Association and The Japanese Gastric Cancer Association.

Entities:  

Keywords:  Gastric cancer; RABL6; circTMC5; miR-361-3p

Mesh:

Substances:

Year:  2021        PMID: 34296378     DOI: 10.1007/s10120-021-01220-6

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  53 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

Review 2.  Functional role of circular RNAs in cancer development and progression.

Authors:  Wei Lun Ng; Taznim Begam Mohd Mohidin; Kirti Shukla
Journal:  RNA Biol       Date:  2018-08-04       Impact factor: 4.652

Review 3.  Functions of circular RNAs and their potential applications in gastric cancer.

Authors:  Yao Ruan; Zhe Li; Yijing Shen; Tianwen Li; Haiyan Zhang; Junming Guo
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2020-01-14       Impact factor: 3.869

Review 4.  Measuring Intragastric Tumor Markers in Gastric Cancer Patients: a Systematic Literature Review on Significance and Reliability.

Authors:  Edoardo Virgilio; Antonella Proietti; Rosaria D'Urso; Patrizia Cardelli; Enrico Giarnieri; Monica Montagnini; Maria Rosaria Giovagnoli; Paolo Mercantini; Genoveffa Balducci; Marco Cavallini
Journal:  Anticancer Res       Date:  2017-06       Impact factor: 2.480

5.  Circular RNAs are a large class of animal RNAs with regulatory potency.

Authors:  Sebastian Memczak; Marvin Jens; Antigoni Elefsinioti; Francesca Torti; Janna Krueger; Agnieszka Rybak; Luisa Maier; Sebastian D Mackowiak; Lea H Gregersen; Mathias Munschauer; Alexander Loewer; Ulrike Ziebold; Markus Landthaler; Christine Kocks; Ferdinand le Noble; Nikolaus Rajewsky
Journal:  Nature       Date:  2013-02-27       Impact factor: 49.962

6.  Natural RNA circles function as efficient microRNA sponges.

Authors:  Thomas B Hansen; Trine I Jensen; Bettina H Clausen; Jesper B Bramsen; Bente Finsen; Christian K Damgaard; Jørgen Kjems
Journal:  Nature       Date:  2013-02-27       Impact factor: 49.962

Review 7.  Emerging Epigenetic Regulation of Circular RNAs in Human Cancer.

Authors:  Jie Wu; Xiaoqian Qi; Lina Liu; Xin Hu; Jingwen Liu; Jianming Yang; Jun Yang; Lu Lu; Zheng Zhang; Shiqing Ma; Hongfa Li; Xinyue Yun; Tong Sun; Yue Wang; Zuomin Wang; Zihao Liu; Wei Zhao
Journal:  Mol Ther Nucleic Acids       Date:  2019-04-19

8.  Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway.

Authors:  Xing Zhang; Sen Wang; Haixiao Wang; Jiacheng Cao; Xiaoxu Huang; Zheng Chen; Penghui Xu; Guangli Sun; Jianghao Xu; Jialun Lv; Zekuan Xu
Journal:  Mol Cancer       Date:  2019-02-04       Impact factor: 27.401

Review 9.  Current prevalence status of gastric cancer and recent studies on the roles of circular RNAs and methods used to investigate circular RNAs.

Authors:  Fei Jiang; Xiaobing Shen
Journal:  Cell Mol Biol Lett       Date:  2019-08-16       Impact factor: 5.787

10.  Circ-HuR suppresses HuR expression and gastric cancer progression by inhibiting CNBP transactivation.

Authors:  Feng Yang; Anpei Hu; Dan Li; Jianqun Wang; Yanhua Guo; Yang Liu; Hongjun Li; Yajun Chen; Xiaojing Wang; Kai Huang; Liduan Zheng; Qiangsong Tong
Journal:  Mol Cancer       Date:  2019-11-13       Impact factor: 27.401

View more
  3 in total

Review 1.  Circular RNAs Involve in Immunity of Digestive Cancers From Bench to Bedside: A Review.

Authors:  Chunyue Chen; Congcong Xia; Hao Tang; Yirun Jiang; Shan Wang; Xin Zhang; Tao Huang; Xiaoqing Yuan; Junpu Wang; Li Peng
Journal:  Front Immunol       Date:  2022-04-04       Impact factor: 8.786

2.  circ_0006089 promotes gastric cancer growth, metastasis, glycolysis, and angiogenesis by regulating miR-361-3p/TGFB1.

Authors:  Ying Zhou; Qilin Zhang; Bingling Liao; Xiaofeng Qiu; Sheng Hu; Qihua Xu
Journal:  Cancer Sci       Date:  2022-04-24       Impact factor: 6.518

Review 3.  Prognostic Roles of ceRNA Network-Based Signatures in Gastrointestinal Cancers.

Authors:  Xin Qi; Xingqi Chen; Yuanchun Zhao; Jiajia Chen; Beifang Niu; Bairong Shen
Journal:  Front Oncol       Date:  2022-07-18       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.